PMID- 21773076
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111110
LR  - 20240511
IS  - 2218-4333 (Electronic)
IS  - 2218-4333 (Print)
IS  - 2218-4333 (Linking)
VI  - 2
IP  - 6
DP  - 2011 Jun 10
TI  - Review of the treatment of metastatic non small cell lung carcinoma: A practical 
      approach.
PG  - 262-71
LID - 10.5306/wjco.v2.i6.262 [doi]
AB  - In recent years, as we have a better knowledge and understanding of the biology 
      of non small cell lung carcinoma (NSCLC), which leads us to targeting biomarkers 
      driving the NSCLC carcinogenesis and metastatic potential, we now have an 
      increased number of options to offer our patients with NSCLC. We also realize the 
      importance of distinguishing squamous and non squamous histology to guide our 
      treatment decisions of NSCLC. The palliative care concomitant with therapies from 
      the very start of the treatment also showed an impact on survival. This review 
      examines the treatment options in all lines of therapy for metastatic NSCLC that 
      have been approved in Canada, the United States, or Europe.
FAU - Hirsh, Vera
AU  - Hirsh V
AD  - Vera Hirsh, Department of Medical Oncology, McGill University Health Centre, 
      Royal Victoria Hospital, Montreal, QC H3A 1A1, Canada.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Clin Oncol
JT  - World journal of clinical oncology
JID - 101549149
PMC - PMC3139036
OTO - NOTNLM
OT  - 1st Line
OT  - 2nd Line
OT  - 3rd Line
OT  - Metastatic
OT  - Non small cell lung carcinoma
OT  - Treatment
EDAT- 2011/07/21 06:00
MHDA- 2011/07/21 06:01
PMCR- 2011/06/10
CRDT- 2011/07/21 06:00
PHST- 2011/03/12 00:00 [received]
PHST- 2011/06/02 00:00 [revised]
PHST- 2011/06/07 00:00 [accepted]
PHST- 2011/07/21 06:00 [entrez]
PHST- 2011/07/21 06:00 [pubmed]
PHST- 2011/07/21 06:01 [medline]
PHST- 2011/06/10 00:00 [pmc-release]
AID - 10.5306/wjco.v2.i6.262 [doi]
PST - ppublish
SO  - World J Clin Oncol. 2011 Jun 10;2(6):262-71. doi: 10.5306/wjco.v2.i6.262.